HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Myeloid neoplasm — Clinical Guidelines

Overview

Myeloid neoplasms encompass a range of disorders including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and other myeloid malignancies characterized by dysregulated hematopoiesis and clonal hematologic abnormalities.

Diagnosis

Utilize both WHO2022 and International Consensus Classification (ICC) guidelines, though significant overlap exists 1.

Genetic testing, including next-generation sequencing, is crucial for identifying specific mutations (e.g., CSF3R, SETBP1, ASXL1) and guiding diagnosis 7 5.

Consider germline predisposition syndromes, which account for up to 10% of cases, through comprehensive genetic screening 4.

Morphologic criteria remain important, especially for rare entities like atypical CML and CNL 7.

Evaluate for specific chromosomal abnormalities such as inv(3)/t(3;3) for targeted management 6.

Management

First-line treatments:

- For AML: Induction chemotherapy regimens (e.g., cytarabine, daunorubicin) 3. - For MDS: Supportive care, hypomethylating agents (e.g., azacitidine, decitabine), or lenalidomide in specific genetic contexts 3.

Anemia management:

- Target TGF-β-SMAD and HIF-PH pathways with appropriate therapeutic approaches 2.

Supportive care:

- Prophylactic platelet transfusions are widely used (95%) 3. - Consider prophylactic tranexamic acid (TXA) despite uncertainty about its benefit (57% usage) 3. - Tailor antimicrobial prophylaxis based on chemotherapy regimen 3.

Special Populations

Elderly patients: Often treated with less-intensive therapy, emphasizing supportive care strategies to minimize complications 3.

Comorbidities: Tailor supportive care measures, such as prophylactic TXA and antimicrobials, considering individual patient factors 3.

Key Recommendations

Utilize both WHO2022 and ICC guidelines for diagnosis, acknowledging potential confusion due to differences 1. (Evidence: Moderate)

Incorporate genetic testing, including CSF3R, SETBP1, and ASXL1 mutations, to refine diagnosis and prognosis 7 5. (Evidence: Moderate)

Implement comprehensive supportive care measures, including prophylactic platelet transfusions and tailored antimicrobial prophylaxis, especially in less-intensive treatment settings 3. (Evidence: Moderate)

References

1 Zureigat H, Adcock B, Nurse DP, Rauf A, Batah H, Ondeck M et al.. Navigating the 2022 International Consensus and World Health Organization Classifications of Hematopathology: A Call for Unified Diagnostic Language. Archives of pathology & laboratory medicine 2025. link 2 Gangat N, Tefferi A. Targeting anemia in myeloid neoplasms. American journal of hematology 2024. link 3 Blankstein AR, Choi N, Mozessohn L, Sanford D, Paulson K, Rimmer E et al.. Supportive care strategies in myelodysplastic syndromes and acute myeloid leukemia in older adults: a national survey of Canadian hematologists. Annals of hematology 2024. link 4 Reinig EF, Rubinstein JD, Patil AT, Schussman AL, Horner VL, Kanagal-Shamanna R et al.. Needle in a haystack or elephant in the room? Identifying germline predisposition syndromes in the setting of a new myeloid malignancy diagnosis. Leukemia 2023. link 5 Wu D, Luo X, Feurstein S, Kesserwan C, Mohan S, Pineda-Alvarez DE et al.. How I curate: applying American Society of Hematology-Clinical Genome Resource Myeloid Malignancy Variant Curation Expert Panel rules for . Haematologica 2020. link 6 Wang HY, Rashidi HH. The New Clinicopathologic and Molecular Findings in Myeloid Neoplasms With inv(3)(q21q26)/t(3;3)(q21;q26.2). Archives of pathology & laboratory medicine 2016. link 7 Dao KH, Tyner JW. What's different about atypical CML and chronic neutrophilic leukemia?. Hematology. American Society of Hematology. Education Program 2015. link 8 Guha AR, Kotwal R, Deglurkar M. Disappear to appear again? Chloroma of the pelvis--a unique osseous presentation. Acta orthopaedica Belgica 2006. link

Myeloid neoplasm